|
UCLA Tumor Immunology Institutional Traning Grant
|
2T32CA009120-41A1
|
$497,990
|
$99,598
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$379,286
|
$151,714
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
$135,085
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Tissue-specific tumor suppressor effects of p53
|
3R01CA200256-04S1
|
$78,178
|
$39,089
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Tissue-specific tumor suppressor effects of p53
|
5R01CA200256-04
|
$409,185
|
$204,593
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Therapeutic Targeting of Malignant Glioma Stem Cells
|
5R35CA197725-05
|
$902,878
|
$451,439
|
LESNIAK, MACIEJ
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference
|
1R01CA219689-01A1
|
$372,340
|
$372,340
|
CARTEGNI, LUCA
|
RUTGERS, THE STATE UNIV OF N.J.
|
|
The Role of the miRNA Cluster at 14q32 in Lipid Regulation and Renal Cancer Biology
|
5R03CA212696-02
|
$74,750
|
$74,750
|
NANJUNDAN, MEERA
|
UNIVERSITY OF SOUTH FLORIDA
|
|
The role of Dclk1 in the initiation of colorectal cancer
|
5R01CA214017-02
|
$338,550
|
$111,722
|
HOUCHEN, COURTNEY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
The Antigen Targeting Core
|
ZIC BC 011030
|
$312,919
|
$156,459
|
Parkhurst, Maria
|
CCR (NCI)
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,187,757
|
$23,755
|
Cooper, Julia
|
CCR (NCI)
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
5F30CA180731-04
|
$49,524
|
$49,524
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeting transducin Beta-like protein 1 in mantle cell lymphoma
|
1K08CA226352-01
|
$227,046
|
$74,925
|
ALINARI, LAPO
|
OHIO STATE UNIVERSITY
|
|
Targeting melanoma hypoxia with lactic acid bacterium L. lactis
|
5R21CA210202-02
|
$167,475
|
$167,475
|
GOMEZ-GUTIERREZ, JORGE
|
UNIVERSITY OF LOUISVILLE
|
|
Targeting glioblastoma stem-like cells with custom-designed viral vectors
|
1R42CA228875-01
|
$300,000
|
$150,000
|
WARRINGTON, KENNETH
|
LACERTA THERAPEUTICS, INC.
|
|
Targeting epigenetic regulators using bacterial macromolecule delivery
|
5R01CA188382-05
|
$307,616
|
$307,616
|
FORBES, NEIL
|
UNIVERSITY OF MASSACHUSETTS AMHERST
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-10
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
|
5R01CA204968-03
|
$506,098
|
$506,098
|
HANES, JUSTIN
|
JOHNS HOPKINS UNIVERSITY
|
|
T-cell receptor gene therapy for cancer
|
ZIA BC 011479
|
$1,424,997
|
$1,068,748
|
Hinrichs, Christian
|
CCR (NCI)
|
|
Surgery Branch Cell Prep Core
|
ZIC BC 010905
|
$897,301
|
$448,651
|
Wunderlich, John
|
CCR (NCI)
|
|
Structural studies with regulatory RNAs
|
ZIA BC 011824
|
$273,106
|
$13,655
|
Le Grice, Stuart
|
CCR (NCI)
|
|
SPORE in Skin Cancer
|
5P50CA174523-05
|
$2,300,000
|
$92,000
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
SPORE in Genitourinary Cancer
|
3P50CA091846-15S1
|
$1,162,609
|
$116,261
|
DINNEY, COLIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
SPORE in Cervical Cancer
|
5P50CA098252-15
|
$2,251,770
|
$247,695
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE for Translational Approaches to Brain Cancer
|
1P50CA221747-01A1
|
$2,300,000
|
$299,000
|
LESNIAK, MACIEJ
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast Cancer
|
5R01CA218025-02
|
$380,586
|
$125,593
|
LIN, CHUNRU
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Self-assembled multifunctional aptamer-complex biomaterial for precision medicine
|
1R01CA224304-01
|
$369,431
|
$369,431
|
ZU, YOULI
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
Role of the Long Non-coding RNA PVT1 in Cancer
|
5R01CA200643-03
|
$446,063
|
$446,063
|
BAGCHI, ANINDYA
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Role of APOBEC3B in Epigenetic Regulation and Transformation in Cancer
|
1F32CA232458-01
|
$58,654
|
$19,356
|
LEVIN-KLEIN, RENA
|
UNIVERSITY OF MINNESOTA
|
|
RNA Therapeutics for Targeted Treatment of Colon Cancer
|
5R01CA186100-05
|
$342,809
|
$342,809
|
GUO, BIN
|
UNIVERSITY OF HOUSTON
|
|
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
|
5R01CA213119-02
|
$504,040
|
$504,040
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
|
5R21CA213114-02
|
$217,282
|
$217,282
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Reporter Gene Technologies for Integrated Cancer Diagnostics
|
5R01CA082214-18
|
$375,250
|
$93,813
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
Regulatory Pathways and Role of VPF/VEGF in Renal Cancer
|
5R01CA078383-20
|
$334,519
|
$334,519
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC JACKSONVILLE
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
$218,588
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Provectors for treatment of ovarian cancer
|
5R01CA207497-03
|
$352,623
|
$352,623
|
SUH, JUNGHAE
|
RICE UNIVERSITY
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
$392,355
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
|
5R21CA216678-02
|
$212,063
|
$106,032
|
BRADLEY, LINDA
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta
|
1R41CA224504-01A1
|
$299,956
|
$299,956
|
SETH, PREM
|
MULTIVIR, INC.
|
|
Ovarian cancer gene therapy using HPV pseudovirion
|
5R01CA183040-05
|
$336,150
|
$336,150
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
|
4R00CA218870-03
|
$248,999
|
$248,999
|
KLEINSTIVER, BENJAMIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
|
5K99CA218870-02
|
|
$0
|
KLEINSTIVER, BENJAMIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimal DNA Brain-Penetrating Nanoparticle (DNA-BPN) Formulation for Glioblastoma (GBM) Treatment
|
5F31CA210610-03
|
$44,524
|
$44,524
|
NEGRON, KARINA
|
JOHNS HOPKINS UNIVERSITY
|
|
Novel targeted adenovirus
|
5R01CA211096-02
|
$348,844
|
$348,844
|
CURIEL, DAVID
|
WASHINGTON UNIVERSITY
|
|
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer
|
1R01CA223788-01
|
$354,559
|
$177,280
|
LI, SONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer
|
4R44CA217534-02
|
$745,151
|
$372,576
|
NGAMCHERDTRAKUL, WORAPOL
|
PDX PHARMACEUTICALS, LLC
|
|
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)
|
5R01CA195503-04
|
$363,623
|
$363,623
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Nano Approaches to Modulate Host Cell Response for Cancer Therapy
|
5U54CA198999-04
|
$2,261,936
|
$226,194
|
HUANG, LEAF
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense
|
5P01CA016038-44
|
$980,728
|
$127,495
|
DIMAIO, DANIEL
|
YALE UNIVERSITY
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
$105,930
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Gene Therapy for this search: $35,380,030
|